Close Menu

You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.

Home › Business, Policy & Funding › Business News › Chembio Inks Commercialization Deal for Dengue, Zika, Chikungunya Tests

Chembio Inks Commercialization Deal for Dengue, Zika, Chikungunya Tests

May 24, 2018
|
staff reporter

NEW YORK (360Dx) – Chembio Diagnostics announced today that it has signed an agreement to commercialize its point-of-care tests for Dengue, Zika, and Chikungunya infection in Brazil with Bio-Manguinhos.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Oct
09
Featured Webinar

Navigating the FDA's EUA Process for Diagnostics in the Present and Future: A Stakeholder Panel Discussion

Sponsored by
PerkinElmer

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.

What's Popular?

In Infectious Disease

  1. US to Distribute 150 Million Abbott SARS-CoV-2 Antigen Tests at No Cost

  2. FDA Reissues Emergency Use Authorization for Hologic SARS-CoV-2 Assay for Asymptomatic Testing

  3. Roche SARS-CoV-2 Lateral Flow Antigen Test Could Meet Significant Demand

    Premium

  4. Cepheid Multiplex SARS-CoV-2, Flu, RSV Test Nabs FDA Emergency Use Authorization

  5. Israeli Startup LessTests Uses Single-Step Pooling Software to Multiply COVID-19 Testing Capacity

    Premium

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.